Resonance Health Limited ACN 006 762 492

Annual General Meeting 26 November 2008







Summary

Our Business:	Resonance Health provides core laboratory and MRI analysis services using advanced, patented technology to assist with the diagnosis and management of disease		
Lead Product:	FerriScan [®] – accurate assessment of liver iron		
Revenue lines:	FerriScan image analysis services Core laboratory services		
Regulatory Approvals:	FDA, TGA, CE, Health Canada, NZ		
Reimbursement:	NZ, parts of Canada and UK		
R&D:	MRI fibrosis scoring test for early stage fibrosis detection		
Cash:	\$2.498M (30 Sept 2008)		
Staff:	10		
Location:	Perth, Western Australia		
Certifications:	ISO:9001, ISO:13485		





Year in Review

- Terminated US Pathology acquisition strategy, reduce board size, terminated employment of US CEO
- ept 07 Renegotiated long term contract with customers (contract values >\$4m 2008-2011)
- ept 07 Commenced FerriScan services to MDS (myelodysplasia) market
- t 07 FerriScan available in Japan
- Oct 07 Commenced FerriScan services to iron overload patients in Australian clinical study
- Nov 07 Clinical study approved for patient outcome assessment
- Dec 07 International Thalassaemia Society recommends FerriScan
- Dec 07 Successful ISO:9001 audit
- Mar 08 FerriScan available in Poland
- Apr 08 Study results suggest the use of FerriScan improves patient outcomes
- May 08 Italian Patient Management Guidelines recommends FerriScan
- June 08 Australian reimbursement application lodged
- June 08 Initial UK Hospitals gain reimbursement for FerriScan
- June 08 Closed year with \$2.4m cash on hand
- June 08 35 new MRI facilities setup for FerriScan throughout the year
- July 08 EU Reimbursement consultants engaged
- July 08 Ontario MOH reimbursement of FerriScan
- Sept 08 FerriScan available in Brazil
- Sept 08 End of quarter cash on hand \$2.5m
- Oct 08 Displayed at International Thalassaemia Conference in Singapore
- Oct 08 FerriScan available in Columbia and Sri Lanka
- Oct 08 Gained approval for Fibrosis study to proceed



FerriScan Market

- Transfusional Iron overload:
 - Thalassaemia
 - Sickle Cell Anaemia
 - Myelodysplasia
- Primary Iron overload
 - Hemochromatosis
 - Excess iron absorption from the diet
- A patients liver iron concentration value is the best measure of total body iron stores.



FerriScan Market

- Hereditary Haemochromatosis
 - Approx 1 in 20 in populations from Northern European descent
- Thalassaemia Major
 - Over 100,000 new severe cases born every year in belt stretching from Middle East through to SE Asia
 - Affects over 1m people world wide
- Sickle Cell Anaemia
 - 72,000 cases in USA
 - Prevalent in Africa
- Myelodysplasia
 - Ave haematologist has 10-20 patients at any one time






FerriScan

- Non-invasive MRI based technique
- Analysis of the image data is performed by Resonance Health at an ISO:9001 quality assured analysis centre
- No special MRI hardware or software required
- Provides clinicians with accurate information required for managing the treatment of patients
- Core laboratory services provided to Pharma companies conducting clinical trials for iron chelators



Example: FerriScan measurements to monitor iron chelation therapy






Market Acceptance

- FerriScan aims to replace liver biopsy as the new 'gold standard' for measuring liver iron concentration.
- Recently published patient management guidelines recommend FerriScan for the management of patient with iron overload:
 - Thalassaemia International Federation: Guidelines for the Clinical Management of Thalassaemia
 - Italian Society of Haematology: Clinical Practice Guidelines for the Management of Iron Overload
 - UK Thalassaemia Society: Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK
 - US Cooley's Anaemia Foundation (US) stated that this technique is "one of the most important advances to come along in the treatment of individuals with thalassaemia"



FerriScan Availability



- FerriScan works on most MRI scanners available today
- The FerriScan team provides clear instructions and on-line support to help radiologists implement the technique
- FerriScan has been successfully implemented in over 20 countries.





Reimbursement

- Australian submission for Medicare funding for FerriScan
 - Decision expected end 2009
- Some UK reimbursement for FerriScan
 - Program to extend this to other hospitals
 - UK representative
- Ontario, Canada MOH reimbursement for FerriScan
 - Program to extend this to other provinces
- Program commenced in USA
- Sales results in Ontario:
 - 120 FerriScans in last 4 months (ave 30 per month) with reimbursement
 - 49 FerriScans in prior 4 months (ave 12 per month)
 - 29 FerriScans in the same 4 month period last year (ave 7 per month)



FibroScreen™

- Aim to develop an accurate test for measuring liver Fibrosis at early disease stage
- Fibrosis Market:
 - Hepatitis 5 million people worldwide
 - Fatty Liver Disease 40 million people in the USA
- Existing tests lack sensitivity at early stage fibrosis
- 18 month project commenced
- Late 2009 review project outcome, commercial viability and ongoing investment





Financial Results

AUD

	2005-6	2006-7	2007-8
FerriScan #	912	1945	1605
FerriScan Revenue*	\$313,532	\$1,868,790	\$1,722,085
Expenses	(\$4,119,663)**	(\$3,071,961)	(\$2,137,015)
Net (Loss) A/ Tax	(\$3,273,957)**	(\$725,319)	(\$41,392)
Cash	\$0.6m	\$2.4m	\$2.4m

* excludes grant and interest income

** excludes impairment of goodwill on consolidation of \$12.786m in 2006





Strategy

- Expand relationship with large Pharma
- Gain reimbursement for FerriScan and follow with marketing push
- Expand revenue base
 - Expand product offerings cardiac iron, liver fibrosis
 - Expand core laboratory service capabilities
- Manage risks
 - Clinical trial revenue
 - Exchange Rate
 - Reimbursement delays
 - Capital